RT Journal Article
SR Electronic
T1 Distinct and shared genetic architectures of Gestational diabetes mellitus and Type 2 Diabetes Mellitus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.16.23286014
DO 10.1101/2023.02.16.23286014
A1 Elliott, A.
A1 Walters, R. K.
A1 Pirinen, M.
A1 Kurki, M.
A1 Junna, N.
A1 Goldstein, J.
A1 Reeve, M.P.
A1 Siirtola, H.
A1 Lemmelä, S.
A1 Turley, P.
A1 FinnGen
A1 Palotie, A.
A1 Daly, M.
A1 Widén, E.
YR 2023
UL http://medrxiv.org/content/early/2023/02/23/2023.02.16.23286014.abstract
AB Gestational diabetes mellitus (GDM) affects more than 16 million pregnancies annually worldwide and is related to an increased lifetime risk of Type 2 diabetes (T2D). The diseases are hypothesized to share a genetic predisposition, but there are few GWAS studies of GDM and none of them is sufficiently powered to assess whether any variants or biological pathways are specific to GDM. We conducted the largest genome-wide association study of GDM to date in 12,332 cases and 131,109 parous female controls in the FinnGen Study and identified 13 GDM-associated loci including 8 novel loci. Genetic features distinct from T2D were identified both at the locus and genomic scale. Our results suggest that the genetics of GDM risk falls into two distinct categories – one part conventional T2D polygenic risk and one part predominantly influencing mechanisms disrupted in pregnancy. Loci with GDM-predominant effects map to genes related to islet cells, central glucose homeostasis, steroidogenesis, and placental expression. These results pave the way for an improved biological understanding of GDM pathophysiology and its role in the development and course of T2D.Competing Interest StatementR.K.W. has received honoraria from The Jackson Laboratory and sponsored travel from the Russell Sage Foundation A.P. is the chief scientific officer for the FinnGen project that has funding from 13 pharmaceutical companies. M.J.D is a founder of Maze Therapeutics. The remaining authors have no competing interests to declare.Funding StatementThe FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and by eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). This work received the following support: A.E. was a research Scholar supported by Sarnoff Cardiovascular Research Foundation, R.K.W. was supported by R01MH101244, M.P. was supported by the Academy of Finland (336825, 338507), P.T. received support by NIH/NIA (R00-AG062787), E.W. received support by the Academy of Finland Center of Excellence program (352796).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53-1041-17.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFinnGen summary data (genome-wide association summary statistics and phenotype data) are made freely available every 6 months. The FinnGen data may be accessed through Finnish Biobanks' FinnBB portal (www.finbb.fi) and THL Biobank data through THL Biobank (https://thl.fi/en/web/thl-biobank).